Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.4K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.4K
Positron Emission Tomography01:29

Positron Emission Tomography

6.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.9K
Types of Radioactivity03:23

Types of Radioactivity

19.3K
The most common types of radioactivity are α decay, β decay, γ decay, neutron emission, and electron capture.
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
19.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Synthetic Strategies Toward DFO*: Enhanced Yield and Purity of a Key Chelator for <sup>89</sup>Zr Chemistry.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Macropa Scaffold Expansion for Actinium-225 Chelation: A Synthetic Strategy, Labeling Kinetics, and Theoretical Calculations.

Inorganic chemistry·2026
Same author

Comparison of two <sup>18</sup>F-fluorinated glycopeptides for PET imaging of the functional liver mass.

EJNMMI radiopharmacy and chemistry·2026
Same author

Advancing towards cancer theragnostic by probing the <sup>225</sup>Ac decay chain with ultra-high-resolution metallic magnetic calorimeter based detectors.

Communications medicine·2026
Same author

Design and Development of an Automated Pipeline for Medical Hyperspectral Image Acquisition, Processing, and Fusion.

Journal of imaging·2026
Same author

Collagen Imaging in Human Intracranial Aneurysms - a Translational Proof-of-Concept Study.

Translational stroke research·2026
Same journal

Charting New Territory: Systematic Evaluation of the Drug Potential of <i>N</i>-Trifluoromethyl Amides, Ureas & Carbamates.

Journal of medicinal chemistry·2026
Same journal

Red-Light-Triggered <i>In Vitro</i> and <i>In Vivo</i> Photocatalytic Cancer Therapy with Polypyridyl Os(II) Photocatalysts.

Journal of medicinal chemistry·2026
Same journal

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal of medicinal chemistry·2026
Same journal

HsClpP-Engaging Selective Mitochondrial Pan-PDK Degraders for Cancer Therapy.

Journal of medicinal chemistry·2026
Same journal

Rational Development of Activatable Prodrugs of the GSTP1 Inhibitor NBDHEX: Turn-On NIR Fluorogenic Drug Delivery with Selective Anticancer Activity.

Journal of medicinal chemistry·2026
Same journal

Recent Highlights in the Discovery and Design of Antibody-Drug Conjugates.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.0K

α Emitter-Labeled Radiopeptides for Targeted α Therapy of Tumors.

Patrick A Cieslik1, Björn Wängler1,2,3, Carmen Wängler2,4

  • 1Heidelberg University, Medical Faculty Mannheim, Clinic of Radiology and Nuclear Medicine, Molecular Imaging and Radiochemistry, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany.

Journal of Medicinal Chemistry
|November 21, 2025
PubMed
Summary
This summary is machine-generated.

Alpha-emitter radiopeptides offer superior tumor therapy compared to beta-emitters. Future research must address challenges to fully utilize targeted alpha therapy (TAT) for cancer treatment.

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.3K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Related Experiment Videos

Last Updated: Jan 10, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.0K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.3K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical therapy

Background:

  • Peptides are crucial tumor-homing agents in nuclear medicine for diagnosis and therapy.
  • Historically, beta-emitter labeled peptides were standard for receptor-specific cancer therapeutics.
  • A shift towards alpha-emitter labeled peptides is emerging due to higher therapeutic efficiency.

Purpose of the Study:

  • To discuss the advantages of alpha-emitter radiopeptides in targeted alpha therapy (TAT) for tumors.
  • To identify and highlight challenges hindering the full potential of alpha-emitter therapy.

Main Methods:

  • Review of current literature on radiopeptide therapy.
  • Analysis of the benefits of alpha emitters over beta emitters.
  • Identification of challenges in the application of targeted alpha therapy.

Main Results:

  • Alpha emitters exhibit significantly higher therapeutic efficiency than beta emitters for tumor treatment.
  • Peptides serve as effective radionuclide carriers due to their favorable properties.
  • The transition to alpha-emitter radiopeptides represents a significant advancement in nuclear medicine therapy.

Conclusions:

  • Targeted alpha therapy (TAT) using alpha-emitter radiopeptides shows great promise for cancer treatment.
  • Overcoming current challenges is essential to fully realize the potential of TAT.
  • Further research is needed to optimize alpha-emitter radiopeptide applications in oncology.